Treatment With Tofacitinib in Refractory Psoriatic Arthritis: A National Multicenter Study of the First 87 Patients in Clinical Practice
Eva Galíndez-Agirregoikoa, Diana Prieto-Peña, José Luis Martín-Varillas, Beatriz Joven, Olga Rusinovich, Rafael B. Melero-González, Francisco Ortiz-Sanjuan, Raquel Almodóvar, Juan José Alegre-Sancho, Ángels Martínez, Agustí Sellas-Fernández, Lara Méndez, Rosario García-Vicuña, Belén Atienza-Mateo, Iñigo Gorostiza, Miguel Ángel González-Gay and Ricardo Blanco on behalf of the Tofacitinib PsA Clinical Practice Collaborative Group
The Journal of Rheumatology October 2021, 48 (10) 1552-1558; DOI: https://doi.org/10.3899/jrheum.201204
Eva Galíndez-Agirregoikoa, Diana Prieto-Peña, José Luis Martín-Varillas, Beatriz Joven, Olga Rusinovich, Rafael B. Melero-González, Francisco Ortiz-Sanjuan, Raquel Almodóvar, Juan José Alegre-Sancho, Ángels Martínez, Agustí Sellas-Fernández, Lara Méndez, Rosario García-Vicuña, Belén Atienza-Mateo, Iñigo Gorostiza, Miguel Ángel González-Gay and Ricardo Blanco on behalf of the Tofacitinib PsA Clinical Practice Collaborative Group
The Journal of Rheumatology October 2021, 48 (10) 1552-1558; DOI: https://doi.org/10.3899/jrheum.201204
- Category
- Health
Be the first to comment